Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Protected Classes Retained For 2011, With Exceptions Process, In Final CMS Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicare Part D formulary requirements for the six "protected" classes will be maintained through 2011 and until the agency establishes otherwise through rulemaking, under a final rule slated for April 15 publication.

You may also be interested in...

CMS Proposes Part D Protected Drug Criteria, Drops Antidepressants And Immunosuppressants

A proposed Medicare rule says under new criteria CMS has developed, antidepressants and immunosuppressants will no longer be protected classes in plan formularies, but antineoplastics, antiretrovirals and anticonvulsants will remain. Antipsychotics will also be protected through 2015 as CMS continues to evaluate the class.

CMS Defines Terms For Part D Protected Classes, Revises Multi-Step Review

CMS' latest take on policy for "protected classes" under Medicare Part D identifies three key issues that will shape how such classes are chosen in the future: defining terms used in the statutory language, a new approach to the agency's previously proposed multi-step process for evaluating classes, and options for public comment on the agency's choices

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts